Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone + lenalidomide in relapsed or refractory CLL
2010-024520-15Phase 2Completed
- Sponsor
- University College London
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and dexamethasone in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University College London. Primary endpoint: Objective response rate at 4 weeks after completion of chemotherapy. Started Jan 2012; status: completed.
02
Drugs
lenalidomidedexamethasone
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2010-024520-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024520-15.